Aravive Inc

NASDAQ:ARAV   3:59:42 PM EDT
4.75
-0.09 (-1.86%)
Earnings Announcements

Aravive Reports Q4 2020 Financial Results

Published: 03/16/2021 11:23 GMT
Aravive Inc (ARAV) - Q4 Loss per Share $0.25.
Aravive - First Patient Dosed in Phase 1b/2 Trial of Avb-500 in Clear Cell Renal Cell Carcinoma in 1q 2021; On-track to Report Topline Data in 2h 2021.
Q4 Earnings per Share View $-0.52 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.35 Million
Adjusted EPS is expected to be -$0.48

Next Quarter Revenue Guidance is expected to be $0.28 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.